ASSOCIATION OF ANTIBIOTICS AND PROTON PUMP INHIBITORS ON CLINICAL ACTIVITY OF FIRSTLINE PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER: 2 YEARS OF REAL WORLD DATA
4CPS-300
EFFECTIVENESS AND SAFETY OF CEMIPLIMAB IN SQUAMOUS CELL CARCINOMA OF THE SKIN IN A THIRD LEVEL HOSPITAL
4CPS-299
PATIENTS’ MISCONCEPTIONS FOLLOWING INITIATION OF ANTINEOPLASTIC TREATMENT FOR COLORECTAL CANCER
4CPS-298
EFFICACY AND SAFETY PROFILE OF ANTI-EGFR TYROSINE KINASE INHIBITOR THERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER
4CPS-297
SPINAL CORD APLASIA CAUSED BY 6-MERCAPTOPURINE IN A CAUCASIAN GIRL WITH ACUTE LYMPHOBLASTIC LEUKAEMIA AND HOMOZYGOUS MUTATION IN NUDIX HYDROLASE 15: CASE REPORT
4CPS-296
IMPACT OF THE COVID-19 PANDEMIC ON CLINICAL LUNG CANCER MANAGEMENT
4CPS-295
IMMUNOTHERAPY FOR CANCER THERAPEUTIC POSITIONING REPORTS: KNOWLEDGE, EXPECTATIONS AND EXPERIENCES THROUGH A NATIONAL SURVEY.
4CPS-294
EFFICACY AND SAFETY PROFILE OF TRIFLURIDINE TIPIRACIL AND REGORAFENIB IN THE TREATMENT OF METASTATIC COLORECTAL CANCER
4CPS-293
EFFICACY AND SAFETY OF CYCLIN DEPENDENT KINASE INHIBITORS IN METASTATIC BREAST CANCER
4CPS-292
EFFECTIVENESS AND SAFETY OF IBRUTINIB IN CHRONIC LYMPHATIC LEUKAEMIA: MULTICENTRE STUDY
4CPS-291
PALBOCICLIB: EARLY NEUTROPENIA AS A PHARMACODYNAMIC MARKER IN A REAL WORLD SETTING?
4CPS-290
BORTEZOMIB INDUCED ACUTE NECROHAEMORRHAGIC PANCREATITIS: A CASE REPORT
4CPS-289
ANALYSIS OF ANTINEOPLASTIC DRUG CONTAMINATION LEVEL IN THE HOSPITAL PHARMACY: PROBLEM MONITORING AND SOLVING
4CPS-288
CLINICAL PHARMACIST'S IMPACT IN IMPROVING THE SAFETY OF THERAPIES FOR PATIENTS USING ORAL ANTICANCER AGENTS: A PROSPECTIVE SINGLE CENTRE STUDY
4CPS-287
IMPACT OF SARS-COV-2 INFECTION IN ACUTE MYELOID LEUKAEMIA PATIENTS: EXPERIENCE OF THE PETHEMA REGISTRY
